Introduction
Phytotherapy has a long tradition in the medical treatment of BPH in Europe. Despite there being no established mechanism of action and no precise classi®cation of the active compounds for many of these drugs, substantial symptom improvement has been reported in previous studies [1, 2] . However, as modern drug therapies are becoming signi®cantly more effective (e.g. a1-receptor blocking agents, 5a-reductase inhibitors), there is an obvious need for valid clinical testing of phytosterol drugs to con®rm their claimed bene®ts.
Currently only two clinical trials have been reported that meet most of the study criteria of the WHO consensus conference for the treatment of BPH [3] . Both studies used b-sitosterol (the trade name for bsitosterol used in this study is Harzol 1 ) as the active treatment in their protocols [4, 5] . The study design (multi-centred, placebo-controlled and double-blind) was similar in both trials and showed statistically signi®cant improvements in BPH-related symptoms and urodynamic values during a 6-month study period.
Results for the 18-month follow-up of our previous trial [4] are now available for the primary (modi®ed Boyarsky symptom score) and other outcome variables, e.g. IPSS, the quality-of-life (QoL) index, maximum urinary¯ow (Q max ) and postvoid residual urine volume (PVR) of the 200 patients originally recruited in the study group.
Patients and methods
After unblinding the 6-month randomized trial [4] both placebo and treated patients were free to choose further treatment or discontinue therapy of any kind. Inclusion criteria for the follow-up evaluation were designed to exclude possible false-positive effects and to maximize the number of patients eligible for evaluation. Therefore, all patients with a follow-up of o16 months (486 days) after recruitment for the double-blind trial were included. To be eligible for analysis patients had to be continuously treated for at least 90% of the follow-up and no changes in treatment were allowed within the last 6 weeks before the follow-up visit. Patients were excluded from analysis if there was: loss to follow-up; surgical intervention for BPH; discontinuation of study medication during the double-blind trial; a1-blocker or ®nasteride therapy during the follow-up; any combination of b-sitosterol with other phytotherapy; and insuf®cient follow-up.
For the 18-month follow-up analysis, six groups resulted from the patients' choice of further therapy. Patients from the former b-sitosterol arm accounted for groups 1±3 according to their further treatment in the open extension and those in the former placebo arm accounted for groups 4±6 (Table 1) .
During the follow-up patients were evaluated according to the original protocol of the double-blind trial. The magnitude of their symptoms was assessed using the modi®ed Boyarsky score and the IPSS, and their Q max and PVR were recorded.
Exclusion criteria applied in 83 patients (36 of the former b-sitosterol group and 47 from the former placebo group) of whom 32 had more than one reason for exclusion ( Table 2 ). Eleven patients were excluded for BPH-related surgery, another seven because they discontinued study medication during the double-blind trial and seven because they were treated with a1-blockers or ®nasteride during the follow-up. Thirty-three patients were excluded from analysis as they were lost to followup. From the remaining 152 eligible patients, a further 25 were excluded because of insuf®cient follow-up. Table 2 also details the distribution between the original groups of patients excluded for each criterion.
The unpaired t-test was used to assess differences between all the variables in the original double-blind trial. The modi®ed Boyarski score in the placebocontrolled study was originally evaluated in an intention-to-treat analysis. Other P values reported (compared with placebo) were considered descriptive only [4] , as are all P values reported in the present analysis. The level of signi®cance was de®ned as a = 0.05 (two-sided).
Results
Of the 200 patients from the original protocol, 117 (59%)
were eligible for the 18-month follow-up analysis; 41% were excluded for various criteria ( Table 2 ). The treatment outcome for the primary and secondary variables is shown in Table 3 . Those in group 1 continued to have a favourable outcome, with all values remaining stable from the end of the double-blind study to the 18-month follow-up. There was no additional effect from the longer treatment period. All improvements at 18 months were signi®cantly better (except for PVR) than in those who never received active treatment (group 5).
Of the former placebo group, those in group 4 improved to the same extent as the treated group in the double-blind trial for all variables (Table 3) . Symptoms and QoL improved more than in those who remained on watchful waiting (group 5), but the changes in Q max and PVR were not signi®cant because there were too few patients. Those in group 5 and those in group 6 (data not shown) had no or minor signs of improvement between the end of the double-blind study and at 18 months of follow-up.
Patients in group 2 showed mild worsening of symptoms and PVR (Table 3) , but compared with the baseline values of the original trial, the improvement remained substantial. Comparing the 18-month followup values between group 2 and group 5, the changes in symptoms and QoL (IPSS) were signi®cant. Patients in group 3 (data not shown) improved slightly compared with those who took no further medication.
Of the initial 200 patients, 15 (7.5%) reported undergoing surgery for BPH during the 18-month follow-up; 12 (6%) of these patients belonged to the former placebo group and three (1.5%) to the former b-sitosterol group. The mean time to surgery was 201 days in the patients on placebo and 441 in those taking b-sitosterol.
Discussion
To date, b-sitosterol has been tested in two randomized, placebo-controlled, double-blind clinical trials [4, 5] , and in many other trials of different design over the last two decades [6±8]. The ®rst two trials were conducted following the WHO consensus criteria [3] , except that b-sitosterol (n = 100) Placebo (n = 100) the study duration was 6 months in both. Both trials have shown b-sitosterol to be better than placebo over the study period for symptoms and uro¯ow variables.
With the criticism that the study duration was insuf®-cient to provide enough information about the long-term results, the present study was designed to investigate the outcome of the original study population of the b-sitosterol group one year after the end of the doubleblind protocol [4] . From the 64 eligible patients taking b-sitosterol in the original study, only 19% chose to discontinue it after unblinding; most of the rest (59%) remained on bsitosterol treatment. In these patients, the results were stable over the 18-month follow-up. Of the 53 eligible former placebo patients, most (66%) chose phytotherapy over watchful waiting (34%). Interestingly, when starting b-sitosterol therapy (group 4), the patients had the same extent of symptom relief as had those taking bsitosterol during the randomized study. Despite the small groups, in general all those who chose sitosterol for further therapy (group 1 and 4) had signi®cantly better symptom relief and QoL scores than those who remained on watchful waiting during the open extension (group 5). Of all eligible patients, most chose drug therapy after unblinding in both the b-sitosterol and placebo groups; overall, these patients had a substantial and lasting favourable effect compared with the symptom severity at randomization. Active treatment was generally better than watchful waiting.
To interpret the present results correctly, the sub- Table 2 Reasons for exclusion from the 18-month follow-up evaluation. Note that exclusion criteria were applied in the order given, e.g. 15 patients had surgical interventions for BPH but four were already excluded as follow-up data were missing, thus the total number of excluded patients increased by only 11 stantial group of 83 patients who were excluded from the follow-up evaluation (41.5% of the original recruited 200 patients) were analysed for possible effects on the results. Three major indicators of treatment failure, e.g. surgical intervention, choice of a1-blocker or ®nasteride therapy, and discontinuation of medication during the randomized trial, were more prevalent in those receiving placebo. In addition, more patients were lost to follow-up in the placebo than in the b-sitosterol group. Results from the randomized study phase for the excluded patients showed no substantial differences in outcome compared with those not excluded. Therefore, no relevant factors appeared to affect the results of the 18-month follow-up caused by the exclusion of these patients. The proportion of patients undergoing BPH-related surgical intervention (7.5%) was about half that reported in the recent PLESS study with ®nasteride [9] . Of these 15 interventions, 12 were in patients receiving placebo and in those who chose no further therapy in the open extension, with only two in those treated with b-sitosterol. These ®ndings further support the bene®cial effect of b-sitosterol therapy. However, as the study was not designed to assess this criterion it remains unclear whether other factors than b-sitosterol were responsible for this effect. Thus, as with many medical therapies for BPH, it is unclear if surgery is postponed rather than prevented in the long-term.
In the open-extension protocol each patient was free to chose their further treatment. When the outcome values for patients after unblinding were compared with their choice of further treatment, no signi®cant factors, e.g. treatment outcome or treatment arm, were predictive in any of the follow-up groups. Therefore, it appears that additional factors other than treatment outcome, e.g. personal or doctor's preferences, may have also been involved in the choice. Of 32 patients who apparently required no further therapy, 18 were in the former placebo group and of 22 patients who changed to other phytotherapy, eight were former placebo patients. This re¯ects the typical wide spectrum of BPH symptom bother and the relative indications for therapy. Thus, as with other medical treatment for BPH, frequent monitoring of symptoms during therapy is advisable and therapy should be interrupted if the symptoms are relieved.
Together with other phytotherapy agents, b-sitosterol is often criticised because the mechanism of action is unknown. As prostatic size remains mostly unchanged during treatment, a substantial endocrine mechanism of action is unlikely. However, as shown in a recent study from our group [10] , b-sitosterol has a signi®cant effect on stromal TGFb production within the prostate in vitro. Whether the induction of TGFb is responsible for symptom relief in patients with BPH remains unclear.
As there are no known major side-effects of b-sitosterol therapy and the effects are maintained over at least 18 months, b-sitosterol should be considered with other medical therapies for patients with symptomatic BPH; however, it remains unclear which type of patient with BPH would bene®t the most from this therapy. In addition, further randomized clinical trials should con®rm the present data, as the relatively few patients and brief duration of the double-blind study limit the conclusions drawn about the long-term results. As there are no pressure¯ow data, this therapy should be considered as symptomatic relief rather than removing obstruction. This should always be considered when symptomatic BPH is treated conservatively with bsitosterol.
